Zika virus vaccines and monoclonal antibodies: a priority agenda for research and development
Ostrowsky J, Katzelnick L, Bourne N, Barrett A, Thomas S, Diamond M, Beasley D, Harris E, Wilder-Smith A, Leighton T, Mehr A, Moua N, Ulrich A, Cehovin A, Fay P, Golding J, Moore K, Osterholm M, Lackritz E, Workgroup Z, Waldorf K, Barrett A, Beasley D, Bennie J, Bourne N, Brault A, Cehovin A, Coelho C, Diamond M, Emperador D, Faria N, Fay P, Golding J, Harris E, Hasanin N, Jaenisch T, Ko A, Lackritz E, Leighton T, Leo Y, Mehr A, Memish Z, Méndez-Rico J, Moore K, Mura M, Ng L, Osterholm M, Ostrowsky J, Peeling R, Rabe I, Salje H, Staples J, Thomas S, Ulrich A, Vanhomwegen J, Wongsawat J. Zika virus vaccines and monoclonal antibodies: a priority agenda for research and development. The Lancet Infectious Diseases 2025 PMID: 40024262, DOI: 10.1016/s1473-3099(24)00750-3.Peer-Reviewed Original Research
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply